Duration of immunotherapy – should we continue ad infinitum?

The optimal duration of immunotherapy treatment for cancer patients is unknown. As the survival data from early immunotherapy trials mature we are beginning to appreciate how durable responses can be post‐discontinuation. The purpose of this brief communication is to comment on treatment duration of immunotherapy in patients with melanoma and non‐small cell lung cancer and to provide practice guidance in support of discontinuation.